Market Overview

Benzinga's Top Upgrades

Share:
Benzinga's Top Upgrades
Related BMY
5 Pharmaceutical Price Target Raises From Jefferies
SunTrust Highlights Upcoming Pharma Calendar, Favorite Names
Eylea Combinations And Array's Play For Melanoma (Seeking Alpha)
Related GNRC
Benzinga's Top Upgrades
Genera Holdings To Acquire Majority Stake Of PR Industrial To 'Dramatically Increase' Global Presence

Analysts at Morgan Stanley upgraded Bristol-Myers Squibb Company (NYSE: BMY) from “equal-weight” to “overweight.” The target price for Bristol-Myers Squibb has been raised from $45 to $60. Bristol-Myers Squibb's shares closed at $48.77 on Friday.

Analysts at Goldman Sachs upgraded Generac Holdings (NYSE: GNRC) from “sell” to “neutral.” The target price for Generac Holdings has been raised from $32 to $49. Generac's shares closed at $50.44 on Friday.

Guggenheim Securities upgraded FMC Technologies (NYSE: FTI) from “neutral” to “buy.” The target price for FMC Technologies is set to $60. FMC Technologies' shares closed at $51.13 on Friday.

Analysts at Bank of America upgraded Astrazeneca PLC (NYSE: AZN) from “underperform” to “neutral.” Astrazeneca's shares closed at $52.74 on Friday.

Latest Ratings for BMY

DateFirmActionFromTo
Jun 2016JefferiesMaintainsHold
May 2016Credit SuisseMaintainsOutperform
Apr 2016Societe GeneraleInitiates Coverage onSell

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: top upgradesUpgrades Analyst Ratings

 

Related Articles (AZN + BMY)

View Comments and Join the Discussion!